315 related articles for article (PubMed ID: 34575992)
61. Continuing challenges and current issues in acute lymphoblastic leukemia.
Kansagra A; Dahiya S; Litzow M
Leuk Lymphoma; 2018 Mar; 59(3):526-541. PubMed ID: 28604239
[TBL] [Abstract][Full Text] [Related]
62. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
63. New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances.
Simioni C; Bergamini F; Ferioli M; Rimondi E; Caruso L; Neri LM
Hematol Oncol; 2020 Feb; 38(1):22-33. PubMed ID: 31487068
[TBL] [Abstract][Full Text] [Related]
64. Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia.
Xu H; Yu H; Jin R; Wu X; Chen H
Cells; 2021 Nov; 10(12):. PubMed ID: 34943855
[TBL] [Abstract][Full Text] [Related]
65. Treatment and biology of pediatric acute lymphoblastic leukemia.
Kato M; Manabe A
Pediatr Int; 2018 Jan; 60(1):4-12. PubMed ID: 29143423
[TBL] [Abstract][Full Text] [Related]
66. [Pediatric acute lymphoblastic leukemia: update on pathophysiology and management].
Kato M
Rinsho Ketsueki; 2018; 59(5):504-510. PubMed ID: 29877240
[TBL] [Abstract][Full Text] [Related]
67. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
68. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
Khan M; Siddiqi R; Tran TH
Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
[TBL] [Abstract][Full Text] [Related]
69. Treatment of pediatric acute lymphoblastic leukemia.
Cooper SL; Brown PA
Pediatr Clin North Am; 2015 Feb; 62(1):61-73. PubMed ID: 25435112
[TBL] [Abstract][Full Text] [Related]
70. "Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL.
Chiaretti S; Jabbour E; Hoelzer D
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):301-310. PubMed ID: 29653823
[TBL] [Abstract][Full Text] [Related]
71. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
72. Therapies on the horizon for childhood acute lymphoblastic leukemia.
Carroll WL; Hunger SP
Curr Opin Pediatr; 2016 Feb; 28(1):12-8. PubMed ID: 26576011
[TBL] [Abstract][Full Text] [Related]
73. [Treatment strategy for B cell precursor acute lymphoblastic leukemia in children].
Koh K
Rinsho Ketsueki; 2022; 63(7):816-825. PubMed ID: 35922953
[TBL] [Abstract][Full Text] [Related]
74. Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses.
Kline KAF; Kallen ME; Duong VH; Law JY
Curr Hematol Malig Rep; 2021 Oct; 16(5):384-393. PubMed ID: 34417955
[TBL] [Abstract][Full Text] [Related]
75. Novel approaches to pediatric leukemia treatment.
Thomas X
Expert Rev Anticancer Ther; 2015; 15(7):811-28. PubMed ID: 26004287
[TBL] [Abstract][Full Text] [Related]
76. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
Dias A; Kenderian SJ; Westin GF; Litzow MR
Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
[TBL] [Abstract][Full Text] [Related]
77. Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects.
Li W; Zhang Y; Kankala RK; Zou L; Chen Z
Pharmacology; 2022; 107(7-8):368-375. PubMed ID: 35390793
[TBL] [Abstract][Full Text] [Related]
78. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
[TBL] [Abstract][Full Text] [Related]
79. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy.
Krishnan V; Rajasekaran AK
Clin Pharmacol Ther; 2014 Feb; 95(2):168-78. PubMed ID: 24013811
[TBL] [Abstract][Full Text] [Related]
80. Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy.
Kotecha RS
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):611-617. PubMed ID: 36485124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
